Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.94 |
| ▸ | IDO1 | P14902 | 1/20 | 0.57 |
| ▸ | AGXT | P21549 | 1/20 | 0.55 |
| ▸ | CA1 | P00915 | 5/20 | 0.50 |
| ▸ | CA2 | P00918 | 3/20 | 0.50 |
| ▸ | CA9 | Q16790 | 3/20 | 0.50 |
| ▸ | CA7 | P43166 | 2/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | TACR1 | P25103 | 2/20 | 0.48 |
| ▸ | CALM1 | P0DP23 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.46 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.46 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.46 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27380 | 0.97 | TSHR (1.00) | TSHRIDO1AGXTCA1CA2 | |
| SCHEMBL5311581 | 0.97 | TSHR (1.00) | TSHRIDO1AGXTCA1CA2 | |
| SCHEMBL9795394 | 0.94 | TSHR (0.94) | TSHRIDO1AGXTCA1CA2 | |
| SCHEMBL9725547 | 0.94 | TSHR (0.94) | TSHRIDO1AGXTCA1CA2 | |
| Water SCHEMBL15535487 | 0.94 | TSHR (0.94) | TSHRIDO1AGXTCA1CA2 | |
| SCHEMBL1009266 | 0.94 | TSHR (0.94) | TSHRIDO1AGXTCA1CA2 | |
| Potassium SCHEMBL586337 | 0.94 | TSHR (0.94) | TSHRIDO1AGXTCA1CA2 | |
| SCHEMBL10317949 | 0.94 | TSHR (0.94) | TSHRIDO1AGXTCA1CA2 | |
| SCHEMBL9491202 | 0.94 | TSHR (0.94) | TSHRIDO1AGXTCA1CA2 | |
| Methane SCHEMBL11192510 | 0.94 | TSHR (0.94) | TSHRIDO1AGXTCA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118001260-A | Dissolving monosodium urate for treating gout | 贺亮 | 2024-05-10 | — | — | CN | disclosed |
| CN-111491625-B | Dissolving monosodium urate for treating gout | 贺亮 | 2023-12-01 | — | — | CN | disclosed |
| US-20210077420-A1 | Methods of Treatment of Gout | HOOPER MARK (GB) | 2021-03-18 | — | — | US | disclosed |
| EP-3723741-A1 | DISSOLUTION OF MONOSODIUM URATE TO TREAT GOUT | Hooper, Mark (GB) | 2020-10-21 | — | — | EP | disclosed |
| CN-111491625-A | Monosodium urate for treating gout | 马克·霍伯 | 2020-08-04 | — | — | CN | disclosed |
| WO-2019116045-A1 | DISSOLUTION OF MONOSODIUM URATE TO TREAT GOUT | HOOPER MARK (GB) | 2019-06-20 | — | — | WO | disclosed |
| US-7842843-B2 | Mixture containing 1,3-butadiene and process for producing the same | KURARAY CO., LTD. (JP) | 2010-11-30 | — | — | US | disclosed |
| US-7728180-B2 | Method for producing ethers | KURARAY CO., LTD. (JP) | 2010-06-01 | — | — | US | disclosed |
| US-20080262272-A1 | Method For Producing Ethers | KURARAY CO., LTD. (JP) | 2008-10-23 | — | — | US | disclosed |
| EP-1795578-A2 | Mixture containing 1, 3-Butadiene and process for producing the same | Kuraray Co., Ltd. (JP) | 2007-06-13 | — | — | EP | disclosed |
| US-20070123738-A1 | MIXTURE CONTAINING 1,3-BUTADIENE AND PROCESS FOR PRODUCING THE SAME | KURARAY CO., LTD (JP) | 2007-05-31 | — | — | US | disclosed |
| EP-1760061-A1 | METHOD FOR PRODUCING ETHERS | KURARAY CO., LTD. (JP) | 2007-03-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070123738-A1 | MIXTURE CONTAINING 1,3-BUTADIENE AND PROCESS FOR PRODUCING THE SAME | TELO2, MSMO1, HBG1 | TSHR 4283/4885IDO1 4046/4885AGXT 3485/4885 |
| US-20080262272-A1 | Method For Producing Ethers | TELO2, PDS5A, TERT | TSHR 657/4885IDO1 3395/4885AGXT 3889/4885 |
| US-20210077420-A1 | Methods of Treatment of Gout | XDH, SLC10A1, LIPA | TSHR 3963/4885IDO1 4149/4885AGXT 240/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.